506 related articles for article (PubMed ID: 19159406)
1. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
3. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
Qu Y; Fang M; Gao B; Chui RW; Vargas HM
J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
[TBL] [Abstract][Full Text] [Related]
4. Other drugs acting on nervous system associated with QT-interval prolongation.
Keller GA; Ponte ML; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):105-11. PubMed ID: 20210727
[TBL] [Abstract][Full Text] [Related]
5. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
6. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
7. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
Nakaya H
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
Tran PN; Sheng J; Randolph AL; Baron CA; Thiebaud N; Ren M; Wu M; Johannesen L; Volpe DA; Patel D; Blinova K; Strauss DG; Wu WW
PLoS One; 2020; 15(11):e0241362. PubMed ID: 33157550
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap CB; Crettol S; Rougier JS; Schläpfer J; Sintra Grilo L; Déglon JJ; Besson J; Croquette-Krokar M; Carrupt PA; Abriel H
Clin Pharmacol Ther; 2007 May; 81(5):719-28. PubMed ID: 17329992
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
12. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
13. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
15. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
16. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
17. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
18. QT alterations in psychopharmacology: proven candidates and suspects.
Alvarez PA; Pahissa J
Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
[TBL] [Abstract][Full Text] [Related]
19. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]